Tenumomeran/raplemomeran plus pembrolizumab missed the PFS end point in HPV16-positive HNSCC.
|Videos|August 3, 2017
Dr. Bauml Discusses Immunotherapy Agents in Head and Neck Cancer
Author(s)Joshua Bauml, MD
Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses immunotherapy agents in head and neck cancer.
Advertisement
Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses immunotherapy agents in head and neck cancer.
Advertisement
Related to this article
The NCCN update adds locally advanced CSCC to the category 2A listing cosibelimab received in metastatic disease in 2025.
Invikafusp alfa now holds fast track status across TMB-H solid tumors that progressed after prior therapy, including checkpoint inhibition.
Patients with resected RCC given adjuvant durvalumab with or without tremelimumab described persistent low-grade toxicities as most disruptive to QOL.
Adjuvant TG4050 was well tolerated and generated long-lasting neoantigen-specific T-cell responses in resected HPV-negative HNSCC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval of Dostarlimab Brings Potential Organ-Sparing Approach in dMMR Locally Advanced Rectal Cancer
2
Casdatifan Demonstrates Activity in Advanced Clear Cell RCC
3
Treatment Tailoring and Weighing Alternative Formulations Support Optimal TKI Deployment in CML
4
HER2+ Maintenance Therapy Approvals and Innovative Brain Metastasis Care Reshape Breast Cancer Management
5